|Bid||100.51 x 800|
|Ask||102.20 x 800|
|Day's range||100.50 - 101.69|
|52-week range||63.22 - 107.24|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||34.16|
|Forward dividend & yield||1.47 (1.45%)|
|Ex-dividend date||16 Aug 2021|
|1y target est||106.36|
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period
These two companies have outperformed the market in the past year, and they are likely to continue doing so.